<DOC>
	<DOCNO>NCT01407393</DOCNO>
	<brief_summary>Glucosanol™ , medical device investigate contains proprietary plant extract natural inhibitor alpha-amylase reduce starch digestion . The rationale study confirm Glucosanol™ ingestion reduce body weight . A double-blind , randomize , placebo-controlled design choose assess efficacy safety Glucosanol™ subject overweight mildly obese .</brief_summary>
	<brief_title>Safety Efficacy Glucosanol Reducing Body Weight Overweight Obese Subjects</brief_title>
	<detailed_description>Preparations reduce absorption calorie dietary carbohydrate could decisively meaningful regulation bodyweight obesity . Hence , Glucosanol™ may use tool treatment obesity weight management reduce carbohydrate absorption . The rationale study confirm Glucosanol™ ingestion reduce body weight . A double-blind , randomize , placebo-controlled design choose assess efficacy safety Glucosanol™ subject overweight mildly obese . The specific hypothesis accept rejected statistical data clinical investigation beneficial effect device weight loss ( kg ) body fat content .</detailed_description>
	<mesh_term>Overweight</mesh_term>
	<mesh_term>Body Weight</mesh_term>
	<criteria>Age 18 60 year BMI 25 35 Expressed desire weight loss Accustomed 3 main meals/day Consistent stable body weight 3 month prior study enrolment Commitment avoid use weight loss product study Commitment adhere diet recommendation Females ' agreement use appropriate birth control method active study period Subject declare write his/her consent participate , understand requirement study willing comply Known sensitivity ingredient device History Diabetes mellitus Fasting blood glucose &gt; 7 mmol/L History clinical sign endocrine disorder may influence body weight ( e.g. , Cushing 's disease , thyroid gland disorder ) Clinically relevant excursion safety parameter Current use antidepressant Presence acute chronic gastrointestinal disease ( e.g. , IBD , coeliac disease . pancreatitis ) Uncontrolled hypertension ( &gt; 160/110 mm Hg ) Stenosis GI tract Bariatric surgery Abdominal surgery within last 6 month prior enrollment History eat disorder bulimia , anorexia nervosa within past 12 month Other serious organ systemic disease cancer Any medication could influence GI function antibiotic , laxative , opioids , glucocorticoid , anticholinergic , antidiarrheal ( e.g. , loperamide ; must stop 1 month study start ) Pregnancy nurse Any medication use product treatment obesity More 3 hour strenuous sport activity per week History abuse drug , alcohol medication Smoking cessation within 6 month prior enrolment Inability comply due language difficulty Participation similar study weight loss program within 3 month prior enrolment Participation study within 4 week prior enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>overweight</keyword>
	<keyword>obesity</keyword>
	<keyword>weight loss</keyword>
	<keyword>body fat</keyword>
	<keyword>waste cirumference</keyword>
	<keyword>satiety</keyword>
	<keyword>appetite</keyword>
</DOC>